Oncogenic mutations in BRAF are common in 50% of melanomas establishing intrinsic resistance linked to constitutive activation of the BRAF/MEK/ERK signaling pathway and leading to uncontrolled cell proliferation [24,60]. Here, MAP2K7 is linked to melanoma.